Impact of Qili Qiangxin Capsules and Sacubitril Valsartan on NT-proBNP Level and Cardiac Function in Patients with Chronic Heart Failure
Objective To explore the effect of Qili Qiangxin capsule combined with sacubitril valsartan in the treatment of chronic heart failure(CHF).Methods 116 CHF patients admitted to our hospital from January 2021 to January 2023 were randomly divided into control group(58 cases)and observation group(58 cases).The control group was treated with sacubitril valsartan sodium tablets,while the observation group was treated with Qili Qiangxin capsules on the basis of the control group.Both groups were treated continuously for 12 weeks.The clinical efficacy,NT-proBNP levels,cardiac function and adverse reactions of the two groups were compared.Results The total effective rate of treatment in the observation group was 91.38％,higher than 77.59％in the control group(P＜0.05).After treatment,the LVEF of the observation group was higher than that of the control group,and the LVEDD,LVESD and NT-proBNP were lower than those of the control group(P＜0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P＞0.05).Conclusions Qili Qiangxin capsules combined with sacubitril valsartan has significant effect in the treatment of CHF patients,can improve the cardiac function indicators,and reduce the NT-proBNP level,which is safe,reliable and worthy of promotion and application.
Chronic heart failureQili Qiangxin CapsuleSacubitril valsartanNT-proBNP levelCardiac function
国家科技期刊平台
NSTL
万方数据
